Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
NCT02964507 · GlaxoSmithKline · PHASE1 · terminated · last registry update 2024-08-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study has been terminated due to meeting protocol defined futility.” | – | Registry record, GlaxoSmithKline |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BRD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-28Results posted on the registry: Novartis Pharmaceuticals, Pelabresib + Ruxolitinib (NCT04603495)
- 2024-09-19Phase 3 first posted: Resverlogix Corp, Apabetalone (NCT06590324)
- 2024-05-06Phase 3 first posted: Novartis Pharmaceuticals, Pelabresib (NCT06401356)
- 2023-11-18Also stopped (terminated): Resverlogix Corp, Apabetalone (NCT04894266)
- 2023-11-18Also stopped (withdrawn): Resverlogix Corp, RVX000222 (NCT03228940)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision